NCT07065682

Brief Summary

This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P75+ for phase_1

Timeline
19mo left

Started Jul 2023

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress65%
Jul 2023Dec 2027

Study Start

First participant enrolled

July 1, 2023

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 15, 2025

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Expected
Last Updated

July 15, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

July 3, 2025

Last Update Submit

July 3, 2025

Conditions

Keywords

Aloe VeraBenign prostate hyperplasiaVEGFProstatedutasterideuroflowmetryprostatic hyperplasia

Outcome Measures

Primary Outcomes (1)

  • Uroflowmetry result

    Qmax of Uroflowmetry result

    12 weeks

Secondary Outcomes (2)

  • Prostatic volume

    12 weeks

  • VEGF

    12 weeks

Study Arms (2)

Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day

EXPERIMENTAL
Drug: Aloevera + dutasteride

Dutasteride

ACTIVE COMPARATOR

Control

Drug: Dutasteride (0.5mg)

Interventions

Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day

Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day

Control

Dutasteride

Eligibility Criteria

Age50 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with BPH clinically or radiologically (prostate volume \> 30 gram, Qmax \<15 mL/s)
  • Willing to participate to the study

You may not qualify if:

  • Clinically or radiologically suspected of having prostatic cancer
  • Previous prostatic surgery
  • Patients with urinary retention
  • Patients with BPH complications: urinary tract infections, urolithiasis, or hydroneprhosis
  • Previously consumed alpha blocker or 5ARI in the last 6 months
  • Have consumed aloe vera extract routinely

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RSUD Karawang

Karawang, West Java, Indonesia

RECRUITING

Related Publications (1)

  • Nugroho E, Azhar A, Gunadi E. Relationship between Prostate Volume and International Prostate Symptom Score (IPSS) Degree of Tamed Prostate Enlargement on Transabdominal Ultrasonography (TAUS) and Transrectal Ultrasonography (TRUS) Examination. Biomed J Indones. 2021;1(7):112-7

    BACKGROUND

MeSH Terms

Conditions

Prostatic Hyperplasia

Interventions

Dutasteride

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

AzasteroidsSteroids, HeterocyclicSteroidsFused-Ring CompoundsPolycyclic Compounds

Central Study Contacts

Achmad Rizky Herda Pratama dr. Achmad Rizky Herda Pratama, Sp.U, S.H, Urologist

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr. Achmad Rizky Herda Pratama, Sp.U, S.H.

Study Record Dates

First Submitted

July 3, 2025

First Posted

July 15, 2025

Study Start

July 1, 2023

Primary Completion

December 1, 2024

Study Completion (Estimated)

December 1, 2027

Last Updated

July 15, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations